Hot Watch List (comments).
This company has innovative experimental approach to treat various kinds of cancer: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
The INCY inhibitor of JAK1/JAK2 INCB018424 is in Phase III safety/efficacy trial for Myelofibrosis with Estimated Primary Completion Date: January 2011
Strongly recommended for investment in early 2011 (Q I). High risk, high reward.
November 30, 2010 by BiotechInvest
It seems like that INCY may release Phase III trial data (COMFORT-1, INCB18424 for myelofibrosis) in December 2010. If trial data are good it will be strong evidence that JAK inhibitors are really effective against cancers. However, trial failure will hit INCY badly i.e. 30-40% losses are possible.
Disclosure: I bought 3k INCY today and will keep it through trial results release. I think that it's very high risk investment, because INCY drug is experimental drug with unpredictable efficacy and side effects. However, drug success will open a new direction in cancer treatment.
December 23, 2010 by BiotechInvest
After very good trial results release INCY pps is in unstable equilibrium. Just for case ("sell on news effect") I activated trigger to sell INCY at market if pps goes below $16.90. Most important that trial gave the evidence of strong science basis of INCY. Thus, INCY become possible acquisition target for big pharmas like Novartis or Lilly.